Peer-reviewed veterinary case report
Survival after toceranib treatment for advanced dog nasal cancer
By Merino-Gutierrez, V et al.·Published in The Journal of small animal practice·2021·Department of Internal Medicine, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015-2020).
- Species:
- dog
Plain-English summary
A group of 23 dogs diagnosed with advanced nasal cancer were treated with a medication called toceranib phosphate to see how it affected their survival. The dogs had either stage III or stage IV nasal carcinoma, and the average survival time was about 139 days. Those with nosebleeds (epistaxis) lived longer on average, around 166 days, compared to those without nosebleeds, who averaged 83 days. Overall, toceranib phosphate was well tolerated, and while most dogs showed some initial improvement, the cancer eventually progressed in many cases.
People also search for: dog nasal cancer treatment · toceranib phosphate for dogs · dog nosebleeds cancer survival · advanced nasal carcinoma in dogs · canine cancer medication effectiveness
Abstract
OBJECTIVE: To determine the median survival time (MST) of dogs with nasal carcinoma treated with toceranib phosphate. MATERIAL AND METHODS: The databases of four Spanish referral hospitals were retrospectively searched for dogs with a diagnosis of nasal tumours presented between January 2015 and October 2020. Dogs treated with radiotherapy or other chemotherapies prior toceranib were excluded. RESULTS: Twenty-three dogs with a confirmed nasal carcinoma treated with toceranib phosphate and with a CT scan for initial staging according to Adams Modified Staging System were included. Nine dogs had a stage III nasal carcinoma whereas 14 dogs had a stage IV nasal carcinoma. No dog had stages I and II nasal carcinoma. The median overall survival time was 139 days. The difference between the MST between dogs with stages III and IV was not statistically significant [P = 0.6, 140 days for stage III (range 46-401) vs 120 days for stage IV (range 23-600)]. Overall, dogs with epistaxis achieved a longer median survival (166 days) than dogs without epistaxis (83 days). Toceranib phosphate was generally well tolerated. Most dogs had an initial clinical benefit followed by progressive disease. SIGNIFICANCE: This is the first study to report the MST in dogs with stages III and IV nasal carcinoma treated with toceranib phosphate. This retrospective study showed that toceranib phosphate decreases the clinical signs associated with nasal carcinomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34131916/